Is TLX or TOVX more undervalued in 2026?

CirclFi compares Telix Pharmaceuticals Limited (TLX) and Theriva Biologics, Inc. (TOVX) using 13 institutional-grade valuation models. TLX has a Quality of Company score of 3.3/10 while TOVX scores 4.0/10.

Which is a better buy — TLX or TOVX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TLX and TOVX valuations compare?

TLX at $9.43 and TOVX at $0.28 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TLX vs TOVX Valuation Comparison 2026 — Intrinsic Value Analysis

TLX

Pharmaceutical Preparations

Telix Pharmaceuticals Limited

Quality

3.3

out of 10

Value Trap

—

Price

$9.43

Last close

Models

12/13

Active

TOVX

Pharmaceutical Preparations

Theriva Biologics, Inc.

Quality

4.0

out of 10

Value Trap

LOW

Price

$0.28

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	TLX Fair Value	TLX Upside	TOVX Fair Value	TOVX Upside
Bayesian DCF	Intrinsic	$2.99	-68.3%	$0.23	-18.8%
Earnings Power Value	Intrinsic	$1.36	-87.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.61	-83.0%	$0.05	-87.6%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TLX vs TOVX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TLX vs TOVX — Which Stock Is More Undervalued?

TOVX scores higher with a 4.0/10 quality rating vs TLX's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Telix Pharmaceuticals Limited (TLX) and Theriva Biologics, Inc. (TOVX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TLX currently trades at $9.43 with a QOC of 3.3/10, while TOVX trades at $0.28 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).